Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for retina diseases, announced its participation in the BTIG Virtual Biotechnology Conference 2024. Russell Trenary, President and CEO, will engage in a fireside chat on Monday, August 5th at 8:00 AM ET.
The company's management team will also be available for one-on-one virtual meetings with qualified investors attending the conference. Interested parties are advised to contact their BTIG representative to schedule meetings with Outlook Therapeutics during the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, OTLK declined 4.87%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET
ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2024 on Monday, August 5, 2024 at 8:00 AM ET.
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. If you are interested in scheduling a meeting with Outlook Therapeutics during the conference, please reach out to your BTIG representative.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and United Kingdom Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD in the first calendar quarter of 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA application to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the BTIG Virtual Biotechnology Conference 2024?
Who will be representing Outlook Therapeutics (OTLK) at the BTIG Virtual Biotechnology Conference?
What type of presentation will Outlook Therapeutics (OTLK) be giving at the BTIG conference?
Can investors meet with Outlook Therapeutics (OTLK) management during the BTIG conference?
What is the main product Outlook Therapeutics (OTLK) is developing?
